Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRG2 | P18507 | 2/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.39 |
| ▸ | SMURF1 | Q9HCE7 | 4/20 | 0.36 |
| ▸ | SMURF2 | Q9HAU4 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.34 |
| ▸ | PDE2A | O00408 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | FASN | P49327 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9911410 | 0.84 | GABRG2 (0.37) | GABRG2GABRB3GABRA5SMURF1SMURF2 | |
| SCHEMBL17069753 | 0.69 | SLC22A12 (0.41) | SLC6A4CYP2D6 | |
| SCHEMBL12693003 | 0.69 | ESR2 (0.39) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL879247 | 0.67 | SLC6A2 (0.57) | SMURF1SMURF2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL17260097 | 0.66 | SMURF1 (0.59) | SMURF1SMURF2 | |
| SCHEMBL9610090 | 0.66 | L3MBTL1 (0.40) | GABRG2GABRB3GABRA5SMURF1KCNH2 | |
| SCHEMBL879149 | 0.65 | SMURF1 (0.34) | GABRG2GABRB3GABRA5SMURF1SMURF2 | |
| SCHEMBL9870878 | 0.64 | SLC6A2 (0.58) | SLC6A2SLC6A4SLC6A3CYP2D6KCNH2 | |
| SCHEMBL9912504 | 0.63 | SLC6A2 (0.57) | SMURF1SMURF2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3107895 | 0.63 | GABRG2 (0.34) | GABRG2GABRB3GABRA5KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8198458-B2 | Non-nucleoside reverse transcriptase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-12 | — | — | US | disclosed |
| US-20090143370-A1 | Non-nucleoside Reverse Transcriptase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143370-A1 | Non-nucleoside Reverse Transcriptase Inhibitors | RTF1, POLR1A, POLR1E | GABRG2 4463/4885GABRB3 4569/4885GABRA5 4630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.